抗生素相关性腹泻 中国就医指南

Antibiotic-Associated Diarrhea (AAD) is a common gastrointestinal adverse effect characterized by the onset of loose or watery stools occurring during or within 8 weeks after antibiotic therapy, in the absence of other identifiable causes. It arises primarily from disruption of the gut microbiota—particularly depletion of commensal anaerobes such as Bifidobacteria and Bacteroides—leading to reduced colonization resistance and overgrowth of pathogenic or toxin-producing organisms. While mild AAD may result from non-infectious osmotic or secretory mechanisms (e.g., bile acid malabsorption, altered short-chain fatty acid metabolism), the most clinically significant form is Clostridioides difficile infection (CDI), responsible for 15–25% of AAD cases and nearly all severe, recurrent, or life-threatening presentations. Epidemiologically, AAD affects an estimated 5–30% of patients receiving systemic antibiotics, with incidence varying by antibiotic class (clindamycin, fluoroquinolones, cephalosporins, and broad-spectrum penicillins carry highest risk), age, and healthcare setting. Community-onset AAD is increasingly recognized, but hospital-acquired cases remain prevalent—especially among older adults, immunocompromised individuals, and those with prolonged hospital stays. Key risk factors include advanced age (>65 years), recent hospitalization or nursing home residence, prior AAD or CDI, concurrent proton pump inhibitor use, immunosuppressive therapy, and underlying gastrointestinal disorders (e.g., IBD). Beyond acute discomfort, AAD significantly impairs quality of life: patients report fatigue, abdominal cramping, urgency, fecal incontinence, sleep disturbance, social withdrawal, and work absenteeism. Recurrent or severe AAD—particularly CDI—can lead to dehydration, electrolyte imbalances, toxic megacolon, sepsis, and mortality, especially in frail elderly populations. Psychological burden—including anxiety about recurrence and dietary restrictions—is underrecognized but clinically meaningful. Early recognition, judicious antibiotic stewardship, and prompt microbiota-targeted interventions are central to mitigating both individual morbidity and broader public health impact.

# 抗生素相关性腹泻（AAD）治疗方案与费用明细（消化内科）

一、非手术/保守治疗方案

适用人群：轻中度腹泻（每日排便≤6次、无发热/脱水/白细胞升高）、未检出艰难梭菌毒素者。

• •停用可疑抗生素（基础干预，0元）
• •口服益生菌（如布拉氏酵母菌、双歧杆菌三联活菌）：30–120元/疗程（7–14天）
• •补液与电解质支持（口服补液盐III）：15–40元/疗程
• •必要检查：粪便常规+隐血+艰难梭菌毒素A/B检测（PCR法）：280–450元

二、药物治疗方案（确诊CDI后）

适用人群：艰难梭菌感染（CDI）阳性、中重度或复发患者。

• •一线药物：口服万古霉素（125mg tid×10d）：800–1,500元/疗程；或非达霉素（200mg bid×10d）：3,200–4,800元/疗程
• •复发/难治性CDI：粪菌移植（FMT，结肠镜途径）：单次8,000–12,000元（含供体筛查、制备、操作及术前肠镜检查2,200–3,500元）

三、特殊复杂/并发症治疗

适用人群：伪膜性肠炎、中毒性巨结肠、脓毒症或需ICU支持者。

• •静脉万古霉素+甲硝唑联合治疗：药费+监护费约12,000–25,000元/周
• •外科会诊评估结肠切除指征（极罕见）：仅限暴发性CDI合并穿孔/休克，全套费用≥80,000元（含急诊手术、ICU、多学科管理）

四、方案快速选择指南

• •预算有限/初发轻症：停药+益生菌+补液（总费用≤200元）
• •确诊CDI中重度：万古霉素方案（总费用≤2,000元）
• •≥2次复发：优先FMT（性价比最优，单次根治率＞85%）
• •伴高热/腹胀/白细胞＞15×10⁹/L：立即住院，启动静脉抗感染+多学科评估